Erez Aminov
CEO and Chairman, Director · Telomir Pharmaceuticals, Inc.
- 2024
- May 23, 2026
- 8
Summary
Latest filing:
Erez Aminov is CEO and Chairman, Director of Telomir Pharmaceuticals, Inc. (TELO). 8 SEC Form 4 filings on record going back to 2024, most recently on 23 May 2026. Most recent open-market trade: sold $57K of MIRA on 27 November 2024. Lifetime open-market sales: $134K.
Recent transactions
5The latest 5 SEC Form 4 transactions reported by Erez Aminov.
Trading pattern
InsiderAlpha's records for Erez Aminov go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same sector
No other insider has filed at Erez Aminov's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Carlyle Group Inc. - $1.63B in MDLN purchases and sales in the last 12 months
- Carlyle Mozart Coinvestment Holdings, L.P. - $1.63B in MDLN purchases and sales in the last 12 months
- WARBURG PINCUS CO. - $1.12B in SHC purchases and sales in the last 12 months
- CP Circle ML Holdco GP, LLC - $1.07B in MDLN purchases and sales in the last 12 months
- TC Group Cayman Investment Holdings, L.P. - $1.07B in MDLN purchases and sales in the last 12 months
- Martine A. Rothblatt - $798.23M in UTHR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Erez Aminov?
Erez Aminov is a corporate insider, tracked as CEO and Chairman, Director of Telomir Pharmaceuticals, Inc. (TELO). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Erez Aminov last file a Form 4?
The most recent primary Form 4 on record is dated 23 May 2026, one of 8 filings going back to 2024.
Has Erez Aminov been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($134K) across all tracked filings.